Skip to content
Oncology Research Hub

Chapel Hill, North Carolina

Cancer clinical trials in Chapel Hill, NC

130 cancer studies are recruiting participants at sites in Chapel Hill as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Chapel Hill at a glance

  • 130 studies are recruiting at a site in Chapel Hill.
  • By phase: Early Phase 1 (1), Phase 1 (10), Phase 1/2 (12), Phase 2 (41), Phase 2/3 (2), Phase 3 (31), No phase (16), Observational (17). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (74), industry (46), government (10).
  • By research area: Breast Cancer (44), Lymphoma (40), Lung Cancer (20), Melanoma (11), Pancreatic Cancer (10), Prostate Cancer (5).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Chapel Hill

Basic details from each study's public record (the 30 most recently updated of 130). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    UNC Lineberger Comprehensive Cancer Center
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT07069595 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT06058377 · updated
  3. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT06995898 · updated
  4. Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • Female participants
    Sponsor
    UNC Lineberger Comprehensive Cancer Center
    Study site
    UNC Cancer Hospital
    Registry record
    NCT07389967 · updated
  5. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    Lineberger Comprehensive Cancer Center
    Registry record
    NCT05633654 · updated
  6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT05879926 · updated
  7. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of North Carolina Medical Center
    Registry record
    NCT07174336 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Lung cancer studies recruiting in Chapel Hill

  1. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UNC Lineberger Comprehensive Cancer Center ( Site 3250)
    Registry record
    NCT07513376 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of North Carolina at Chapel Hill
    Registry record
    NCT07659782 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of North Carolina at Chapel Hill
    Registry record
    NCT07002034 · updated
  4. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of North Carolina Medical Center
    Registry record
    NCT06119581 · updated
  5. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    University of North Carolina at Chapel Hill
    Registry record
    NCT06667908 · updated
  6. Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    UNC Health - University of North Carolina
    Registry record
    NCT07288177 · updated
  7. A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT07293247 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Chapel Hill

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT03866382 · updated
  2. Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT06632977 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Melanoma studies recruiting in Chapel Hill

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    UNC Hospitals, The University of North Carolina at Chapel Hill
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Lymphoma studies recruiting in Chapel Hill

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT06724237 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of North Carolina Medical Center ( Site 0136)
    Registry record
    NCT06890884 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT05675410 · updated
  6. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of North Carolina
    Registry record
    NCT06091254 · updated
  7. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT06337318 · updated
  8. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT03150693 · updated
  9. Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT04803201 · updated
  10. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT05976763 · updated
  11. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT07321652 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Chapel Hill

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US035
    Registry record
    NCT07522073 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of North Carolina
    Registry record
    NCT07644559 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.

Ask about studies near Chapel Hill

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in North Carolina

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call